CRIS Curis, Inc.
Financings ·
Curis sold shares and pre-funded warrants at an effective $0.51 a share, with common warrants at $0.60. A.G.P./Alliance Global Partners, the lead placement agent, earns a 6.5% cash fee on the gross proceeds.
The emavusertib developer sold preferred stock with three warrant series at $0.75, one of them timed to an enrollment goal in its leukemia trial.
Nasdaq staff said Curis did not regain compliance with the $35,000,000 market value requirement by August 20, 2025. Curis must request a hearing by August 28, 2025; the request keeps its stock listed during the appeal.
Curis missed Nasdaq's $35 million market value rule and must ask for a hearing by August 28, 2025 to avoid delisting. It says it will ask, and its shares stay listed while a panel decides.
Nasdaq told Curis that its listed securities were worth less than $35,000,000 for 30 consecutive business days. The company has until August 20, 2025 to regain compliance.
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$7.6 million | -$43.4 million |
| Cash from operations | -$27.2 million | -$39.6 million |
| Cash and equivalents | $5.1 million | $20.0 million |
| Short-term investments | $0 |
Our latest story on this, dated Aug 22, 2025: "Curis gets Nasdaq delisting determination over market value rule, plans to appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 7, 2026: "Curis raises $20.2 million up front in a PIPE that could bring in up to $80.8 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 27, 2025: "Curis gets Nasdaq deficiency notice on market value of listed securities". The story links the filing or release it is based on. Read the story.
Curis, Inc. trades under the ticker CRIS on NASDAQ.
Curis, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:CUS1; LS:A42DTL; LSX:A42DTL.
The SEC Central Index Key (CIK) for Curis, Inc. is 1108205. Its filings are on SEC EDGAR.
2,090,077 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Curis, Inc. under United States.
Our directory classifies Curis, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Curis, Inc. is US2312694084.
aibio.space lists Curis, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Curis, Inc. reported a net loss of $7.6 million for the fiscal year ended Dec 31, 2025, and used $27.2 million of cash in operations, per its annual report to the SEC.
$5.1 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Curis, dated Oct 19, 2026: "Curis agrees to sell stock and warrants for about $8.5 million in gross proceeds". Curis sold shares and pre-funded warrants at an effective $0.51 a share, with common warrants at $0.60. A.G.P./Alliance Global Partners, the lead placement agent, earns a 6.5% cash fee on the gross proceeds. Source.
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Filed a final prospectus for a securities offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.02,5.03,5.07,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.02,2.01,2.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.02,5.03,5.07,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio